Edgewise Therapeutics, Inc.
NASDAQ:EWTX
25.67 (USD) • At close March 14, 2025
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) USD.
| 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Omzet
| 0 | 0 | 0 | 0 | 2.252 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Kosten van de omzet
| -1.059 | 0 | 0.534 | 0.525 | 0.533 | 0.448 | 0.437 | 0.241 | 0.092 | 0.165 | 0.154 | 0.127 | 0.078 | 0.064 | 0.051 | 0.079 | 0 | 0 | 0 | 0 |
| Brutowinst
| 1.059 | 0 | -0.534 | -0.525 | 1.719 | -0.448 | -0.437 | -0.241 | -0.092 | -0.165 | -0.154 | -0.127 | -0.078 | -0.064 | -0.051 | -0.079 | 0 | 0 | 0 | 0 |
| Brutowinstmarge
| 0 | 0 | 0 | 0 | 0.763 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Onderzoek- en ontwikkelingskosten
| 37.323 | 32.222 | 30.2 | 27.221 | 27.684 | 23.786 | 19.559 | 19.876 | 16.612 | 13.894 | 12.402 | 11.124 | 9.088 | 9.88 | 7.861 | 5.36 | 5.139 | 3.238 | 3.639 | 2.967 |
| Algemene en administratieve kosten
| 9.17 | 8.21 | 7.427 | 7.059 | 6.178 | 5.666 | 5.78 | 5.828 | 5.467 | 4.368 | 4.089 | 3.702 | 3.734 | 3.196 | 2.599 | 1.497 | 1.205 | 0.405 | 0.318 | 0.281 |
| Verkoop- en marketingkosten
| 0.106 | 0 | -0.054 | -0.052 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Verkoop-, algemene en administratieve kosten
| 9.276 | 8.21 | 7.373 | 7.007 | 6.178 | 5.666 | 5.78 | 5.828 | 5.467 | 4.368 | 4.089 | 3.702 | 3.734 | 3.196 | 2.599 | 1.497 | 1.205 | 0.405 | 0.318 | 0.281 |
| Overige kosten
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bedrijfskosten
| 46.599 | 40.432 | 37.573 | 34.228 | 33.862 | 29.452 | 25.339 | 25.704 | 22.079 | 18.262 | 16.491 | 14.826 | 12.822 | 13.076 | 10.46 | 6.857 | 6.344 | 3.643 | 3.957 | 3.248 |
| Bedrijfsresultaat
| -45.54 | -40.432 | -38.107 | -34.753 | -33.862 | -29.452 | -25.339 | -25.704 | -22.079 | -18.262 | -16.491 | -14.826 | -12.822 | -13.076 | -10.46 | -6.857 | -6.344 | -3.643 | -3.957 | -3.248 |
| Bedrijfsresultaat ratio
| 0 | 0 | 0 | 0 | -15.036 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Totaal overige inkomsten en kosten netto
| 5.878 | 6.303 | 6.61 | 6.228 | 3.719 | 3.739 | 3.87 | 2.866 | 2.664 | 0.764 | 0.424 | 0.166 | 0.126 | 0.127 | 0.107 | 0.042 | 0.002 | 0.001 | 0.003 | 0.063 |
| Inkomen voor belasting
| -39.662 | -34.129 | -31.497 | -28.525 | -30.143 | -25.713 | -21.469 | -22.838 | -19.415 | -17.498 | -16.067 | -14.66 | -12.696 | -12.949 | -10.353 | -6.815 | -6.342 | -3.642 | -3.954 | -3.185 |
| Inkomen voor belasting ratio
| 0 | 0 | 0 | 0 | -13.385 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Belastingkosten
| -0.482 | 0 | 0 | 0.482 | 3.604 | -0.497 | 0.339 | -3.107 | -2.664 | -0.764 | -0.424 | -0.166 | 42.813 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Nettowinst
| -39.662 | -34.129 | -31.497 | -28.525 | -30.143 | -25.713 | -21.469 | -19.731 | -16.751 | -16.734 | -15.643 | -14.494 | -12.696 | -12.949 | -10.353 | -6.815 | -6.342 | -3.642 | -3.954 | -3.185 |
| Nettowinstmarge
| 0 | 0 | 0 | 0 | -13.385 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| WPA (Winst Per Aandeel)
| -0.42 | -0.36 | -0.34 | -0.33 | -0.47 | -0.41 | -0.34 | -0.31 | -0.26 | -0.32 | -0.32 | -0.29 | -0.26 | -0.26 | -0.21 | -4.37 | -0.31 | -0.18 | -0.19 | -0.16 |
| Verwaterde WPA
| -0.42 | -0.36 | -0.34 | -0.33 | -0.47 | -0.41 | -0.34 | -0.31 | -0.26 | -0.32 | -0.32 | -0.29 | -0.26 | -0.26 | -0.21 | -4.37 | -0.31 | -0.18 | -0.19 | -0.16 |
| EBITDA
| -47.095 | -39.83 | -37.627 | -34.28 | -33.379 | -29.003 | -24.915 | -25.509 | -21.991 | -18.162 | -16.394 | -14.699 | -12.744 | -13.012 | -10.409 | -6.778 | -6.294 | -3.593 | -3.912 | -3.208 |
| EBITDA ratio
| 0 | 0 | 0 | 0 | -14.8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |